Section Arrow
Quote
NKTR.NASDAQ
- Nektar Therapeutics
Quotes are at least 15-min delayed:2026/06/06 03:00 EDT
Regular Hours
Last
 57.32
-1.99 (-3.36%)
Day High 
60 
Prev. Close
59.31 
1-M High
87.565 
Volume 
1.03M 
Bid
56.75
Ask
62.4
Day Low
56.81 
Open
59.24 
1-M Low
57.83 
Market Cap 
2.00B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 63.7 
20-SMA 69.29 
50-SMA 76.77 
52-W High 109 
52-W Low 7.99 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.93/-9.31
Enterprise Value
2.07B
Balance Sheet
Book Value Per Share
17.05
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
55.23M
Operating Revenue Per Share
2.61
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BCDABioCardia Inc.1.03+0.111+12.08%-- 
BGMSBio Green Med Solution Inc1.5+0.44+41.51%0.3PE
CMNDClearmind Medicine Inc.3.98+1.07+36.77%-- 
ADTXAditxt Inc.0.0621-0.0149-19.35%-- 
RXRXRecursion Pharmaceuticals3.315-0.485-12.76%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.